Dr Antonio Gallo
Disclosure details
Antonio Gallo has received grants and personal fees from Amgen, Sanofi and Regeneron, Mylan Viatris, MSD, Akcea Therapeutics, Amryt, Servier, Novartis and Ultragenyx.Head of the Lipid Clinic and Cardiovascular Prevention Unit and Associate Professor, Sorbonne University, Pitié-Salpêtrière Hospital, Paris, France
After completing his training in Internal Medicine at Sapienza University of Rome, Dr Gallo obtained a PhD in Physiology, Physiopathology and Therapeutics at Sorbonne University. His clinical activity focuses on the diagnostic and therapeutic management of genetic dyslipidaemias, as well as cardiovascular risk stratification of a large cohort of primary prevention subjects. His research interests include lipid metabolism, severe forms of genetic dyslipidaemias, especially familial hypercholesterolemia and familial chylomicronaemia syndrome, residual risk in primary and secondary prevention, and imaging in atherosclerosis. His current projects are focused on vascular calcifications in familial hypercholesterolemia and their role in cardiovascular risk refining and prediction, retinal microvascular remodeling in cardiometabolic disease, and Lp(a) in secondary prevention cohorts. He is principal investigator of two ongoing studies on familial hypercholesterolemia and several investigational therapeutic phase 3 trials. He is a member of EAS (member of the Young Fellows of EAS 2019-2022), French Atherosclerosis Society NSFA (member of the scientific committee on the French registry of Familial Hypercholesterolemia), French Society of Cardiology (Member of the working group on heart and Metabolism).
